Guardant Health (GH) Co-ceo Amirali Talasaz Sells 111,804 Shares
Recent insider filings show transactions by Guardant Health leaders alongside an upbeat set of analyst targets as the precision oncology firm heads toward its next financial update.
Reviewed by automated data checks against the source filing. How we make and check alerts
Amirali Talasaz, Co-Chief Executive Officer at Guardant Health, Inc. ($GH), sold 111,804 shares on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GH is up 13.1% after 1 week, down 2.5% after 1 month and up 6.3% to date (from the $149.22 close on Jun 26, 2026).
GH
Guardant Health, Inc.
Key Points
- Guardant Health Co-CEO Amirali Talasaz picked up 111,804 shares on June 26, 2026, valued at $467,340.72.
- The precision oncology stock trades near $153.74, well above its 200-day moving average of $120.63.
- Wall Street maintains a strong buy consensus on the company with a mean price target of $196.38 across 26 analysts.
Get $GH trade alerts by text
We text you when insiders, Congress or big funds trade $GH. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Guardant Health, Inc. alert may contain errors. Disclosures
Guardant Health Executive Stock Activity
Guardant Health, Inc. (NasdaqGS: GH) recently logged key insider movements, highlighted by Co-Chief Executive Officer Amirali Talasaz acquiring 111,804 shares on June 26, 2026, for a total value of $467,340.72. This transaction adds to leadership context at the precision oncology company, following earlier disclosures such as a planned sale by director Alex Azar II of 69 shares on October 14, 2026, at an average price of $159.89 for a total value of $11,032.41.
Guardant Health Stock Trades Near Recent Levels
The company's shares change hands around $153.74 on Wednesday, reflecting a dynamic period for the diagnostic firm. The stock has spanned a 52-week low of $55.38 and a high of $183.51. Its 50-day moving average sits at $161.34, while the 200-day moving average rests lower at $120.63, pointing to solid gains over the medium term.
Wall Street Analyst Outlook and Targets
Analyst firms remain broadly optimistic about the diagnostics provider, adjusting targets ahead of the scheduled October 28, 2026 earnings release. On October 13, 2026, Morgan Stanley maintained its Overweight rating and lifted its target to $200.00 from $185.00. Barclays kept an Overweight rating on October 7, 2026, raising its target to $220.00 from $200.00. Guggenheim maintained a Buy rating with a $200.00 target on October 1, 2026, and UBS held a Buy rating with a $225.00 target on September 9, 2026. Rothschild & Co initiated coverage with a Buy rating and a $203.00 target on September 8, 2026, while BTIG reiterated a Buy rating at $195.00 on September 2, 2026. Piper Sandler maintained an Overweight rating with a $193.00 target on August 4, 2026, alongside Stephens & Co. keeping an Overweight rating with a $195.00 target on the same day. Overall, the company carries a strong buy recommendation backed by 26 analysts.
Company Operations in Precision Oncology
Based in Palo Alto, California, Guardant Health focuses on precision oncology, offering blood and tissue tests designed for tumor mutation profiling and cancer screening. Its portfolio includes the Guardant360 test and the Shield blood test for colorectal cancer screening. These offerings aim to deliver genomic and epigenomic insights to help clinicians and biopharmaceutical partners guide cancer research and patient care.
What to Watch Next for Guardant Health
Investors are keeping a close watch on the upcoming financial report scheduled for October 28, 2026, which will provide fresh data on revenue growth and operational progress. Insider transactions and analyst target updates offer additional context on sentiment, though they reflect individual planning and third-party projections rather than definitive investment advice.
Related Filing Alerts
Source: Amirali Talasaz's Form 4 filing on $GH (Jun 26, 2026). Find the original filing: GH Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts